The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | G | Genito urinary system and sex hormones | |
2 | G04 | Urologicals | |
3 | G04B | Other urologicals, incl. antispasmodics | |
4 | G04BE | Drugs used in erectile dysfunction | |
5 | G04BE09 | Vardenafil |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
Route | Amount |
---|---|
ORAL - Oral | 10 mg |
Active Ingredient | Description | |
---|---|---|
Vardenafil |
Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5 (PDE5), the most prominent PDE in the human corpus cavernosum. Vardenafil is an oral therapy for the improvement of erectile function in men with erectile dysfunction. In the natural setting, i.e. with sexual stimulation it restores impaired erectile function by increasing blood flow to the penis. |
Title | Information Source | Document Type | |
---|---|---|---|
LEVITRA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
STAXYN Tablet, orally disintegrating | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
VIVANZA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.